J&J settles Risperdal suit as trial begins; AZ ups its bet in China; Concussion claims irk FDA;

 @FiercePharma: Truvada use expected to be limited in U.S. Story | Follow @FiercePharma

> Johnson & Johnson ($JNJ) says it has settled a Risperdal lawsuit on the first day the trial was to begin over the potential harm caused by the antipsychotic drug. Story 

> AstraZeneca ($AZN) has a new joint venture deal with Chinese drugmaker WuXi AppTec to work on biotech drugs there, as the British company ups its bet on China. Story 

> Merck ($MRK), which is trying a new approach to tapping the potentially huge market for insomnia meds, has more postive data to report ahead of a possible approval from the FDA. Release

> Lundbeck is upping its stake in Finland's Biotie Therapies to 4.6%, and negotiated new terms over Selincro, the new opioid system modulator, the two companies are developing. Story 

> Boehringer Ingelheim is moving further into diabetes work having inked a new pact with the Swiss university ETH Zurich to study the the underlying factors of diabetes and obesity. Item

Medical Device News

 @FierceMedDev: Budget battles could unravel the massive device/drug user fee renewal agreed to earlier this summer. More | Follow @FierceMedDev

 @MarkHFierce: Another day, another 510(k) for an Impella heart pump variation. The company is working hard to broaden its market. Release | Follow @MarkHFierce

 @DamianFierce: San Antonio's BiO2 Medical pulled in $12M to market its venous catheter. News | Follow @DamianFierce

> Cook expands into ENT device arena. More

> Minnesota medtech accelerator debuts, with Medtronic vet at the helm. Item

Biotech News

 @FierceBiotech: What's killing biopharma's R&D success rate? Story | Follow @FierceBiotech

 @JohnCFierce: AZ does a China development deal on RA drug with WuXi AppTech. Kinda similar to SFJ pacts. Look for more of these. Report | Follow @JohnCFierce

> What's killing biopharma's R&D success rate? More

> Geron in meltdown as lead cancer drug crumbles in Phase II. Report

> Atlas R&D group banks $8M in virtual development deal. Story

> Peregrine soars on promising survival data for lung cancer drug. Article

Biotech IT News

> Pharma flocks to social media analytics. Story

> Pinterest attracts more pharma outfits. Report

> ENCODE generates 15 trillion bytes of data for researchers. Article

> Informatics research may kill old-school databases. More

CRO News

> Top Emerging CRO Markets. Special Report

> Icon teams with Dublin university for drug development. Item

> FDA slaps DPT with warning letter over sterility concerns. Article

> CMO Patheon sells off clinical packaging biz. More

And Finally... A supplement maker is butting heads with the FDA which today issued warning letters to PruTect Rx, of Highlands Ranch, CO, and Trinity Sports Group of Plano, TX, for promoting products labeled as dietary supplements with claims to treat concussions and prevent or treat post-concussion syndrome and other neurological disorders. Release

Suggested Articles

The triple combo era in cystic fibrosis is here thanks to Vertex' new OK. Five months ahead of schedule, the FDA green-lighted Trikafta Monday.

On the heels of settling bellwether cases for $45 million, Teva is offering $250 million cash and $23 billion in drugs to end all its opioid lawsuits.

Under assault in the anti-inflammatory market, J&J has focused on expanding Stelara beyond dermatology—and it just took a big step in that direction.